Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Ulrich Kutschera
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory loss and behavioral changes. There are currently no known treatments or medications for AD. Nitric oxide (NO) has long been regarded as a component of the neurotoxic insult brought on by Alzheimer's disease neuroinflammation.
However, this perception is being altered by focusing on early developments, prior to the onset of cognitive symptoms. This has brought to light NO's compensatory, neuroprotective function, which increases neuronal excitability to safeguard synapses. Modulation of voltage-gated potassium channel activity (Kv7 and Kv2) is one potential mechanism by which NO can increase excitability. An important next step for the field is to determine the ionic mechanisms and signaling pathways that mediate this protection. A potential therapeutic option for preventing synapse loss early in disease could be found by harnessing the protective function of NO and related signaling pathways.